Ангиогенные факторы и стимуляция неоангиогенеза при ишемической болезни сердца
Диссертация
В связи с вышеизложенным целью настоящей работы была оценка гуморальной и тканевой экспрессии стимулирующих и подавляющих ангиогенез эндогенных факторов у больных ИБС до и после различных вариантов реваскуляризации миокарда как критерия целесообразности терапевтического ангиогенеза, а также создание препарата для стимуляции неоангиогенеза в ишемизированном миокарде на основе гена VEGF человека… Читать ещё >
Список литературы
- Aldons J.L., Atherosclerosis, Nature, 2000, 407, 233−241.
- Arras M., et al., Enhancement of monocyte recruitment and activation by lipopolysaccharide leads to an increase of capillary sprouting in a rabbit model of hindlimb ischemia., Circulation, 1996, 94, 1−608.
- Banks R.E., Forbes M.A., Kinsey S.E. et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br.J.Cancer, 1998, 77:956.
- Barleon В., et al., Migration of human monocytes in response to VEGF is mediated via the VEGF receptor flt-1., Blood, 1996, 87, 3336−3343.
- Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischaemia., Circulation, 1998, 97: 1114−1123.
- Benjamin L.E., Hemo I., Keshet E.A. A placticity window for blood vessel remodelling is defined by pericyte coverage of preformed endothelial network and is regulaited by PDGF-B and VEGF., Development, 1998, 125: 1591−1598.
- Birkedal-Hansen, H. Moore, W. G. I., Bodden, et al. Matrix Metalloproteinases: A Review. Crit.Rev.Oral Biol.Med., 1993, 4:197−250.
- Bucay M., et al., Impaired adaptive vascular growth in hyperholesterolemic rabbit., Atherosclerosis, 1998- 139, 243−251.
- Cao Y., Progress in Molecular and Subcellular Biology-Inhibitors of Cell Growth, 1998, (Springer, Berlin- Heidelberg- London- New York), vol.20, 161−176.
- Carmeliet P., Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380, 435−439.
- Carmeliet P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice kicking the vascular endothelial growth factor isoforms VEGF 164 and VEGF188., Nature Med., 1999, 5: 1359−1364.
- Casey R, Li WW. Factors controlling ocular angiogenesis. Am. J. Ophthalmol., 1997, 124:521−529.
- Chiron Corporation. Chiron announces preliminary findings from phase II clinical trial of FGF-2. http://www.prnewswire.com/m.icroCHIR Company Press Release 12 March 2000.
- Chu-Huang Chen, et al., Oxidised low-density lipoproteins inhibit endotelial cell proliferation by suppressing bFGF expression., Circulation, 2000, 101, 171−177.
- Cuevas P., et al. Hypotensive activity of fibroblast growth factor. Science, 1991, 254:1208−1210.
- Coussens LM, et al. Inflammatory mast cells up-regulate angiogenesis during squamos epithelial carcinogenesis. Genes Dev., 1999, 13:1382−1397.
- Cuevas P., et al., Vascular response to bFGF when infused onto the normal adventitia or into the injured media of the rat carotid artery., Circulation Res., 1991, 69, 360−369.
- Da 'is S, Aldrich TH, Jones PF, et al. Isolation of angiopoetin-1, a ligand for the TIE2 receptor by secretion-trap expression cloning. Cell, 1996, 87:1161−1169.
- Dettman R.W., Denetclaw W.Jr., Ordahl C.P., Bristow J. Common epicardial origion of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in avian heart., Dev. Biol., 1998, 193: 169−181.
- Dumont DJ et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science, 1998, 282:946−949.
- Dvorak H.F., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am.J.Pathol., 1995, 146:1029−1039.
- Edelman E.R., et al. Basic fibroblast growth factor enchances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries., J.Clin.Invest., 1992, 89, 465−473.
- Eliceiri BP, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell., 1999, 4:915−924.
- Ferrara N, Alitalo K. Clinical aplications of angiogenic growth factors and their inhibitors. Nat. Med., 1999, 5:1359−1364.
- Ferrara N., Carver-Moore K, Chen H, et al., Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene., Nature, 1996, 380, 439−442.
- Ferrara N. et al. Role of vascular endotelial growth factor in the regulation of angiogenesis. Kidney Int., 1999, 56, 794−814.
- Folkman J & Sching Y. Angiogenesis. J. Biol. Chem., 1992, 267:10 931−10 934.
- Folkman J., Tumor angiogenesis: therapeutic implications (review)., New Engl. J.Med., 1971,285, 1182−1186.
- Fuhrmann-Benzakein E., Ma M.N., Rubbia-Brandt L. et al. Elevaited levels of angiogenic cytokines in the plasma of cancer patients. Int.J.Cancer, 2000, 85:40.
- Gale NW & Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoetins, end ephrins in vascular development. Genes Dev., 1999, 13:1055−1066.
- Gordon S., et al., Macrophages in tissuses and in vitro. Curr.Opin.Immunol., 1992, 4, 25−32.
- Gordon S., et al., Molecular immunobiology of macrophages: recent progress., Curr.Opin.Immunol., 1995, 7, 24−33.
- Harada K., et al. Vascular endothelial growth factor in chronic myocardial ischemia. Am. J. Physiol., 1996, 270: H1791-H1802.
- Haralabopoulos G, Grant DS, Kleinman HK, Maragoudakis ME. Trombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am. J. Physiol., 1997, 273: C239-C245.
- Hariawala MD et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J. Surg. Res., 1996, 63:77−82.
- Hashimoto E. et al. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am. J. Physiol., 1994, 267: H1948-H1954.
- Henry TD, Annex BH, Azrin MA, et al. Double blind, placebo-controlled trial of recombinant human vascular endothelial growth factor: the VIVA Trial. J. Am. Coll. Cardiol., 1999, 33:384A.
- Henry TD et al. Results of intracoronary recombinant human vascular endothelial growth factor (RhVEGF) administration trial. J. Am. Coll. Cardiol., 1998, 31:65A.
- Hertig A.T. Angiogenesis in the early human chorion and in the primary placenta of the macaque moncey. Contrib. Emdryol. Carnegie Inst., 1935, 25:37−43.
- Heymans S et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med., 1999, 5:1135−1142.
- Horn DB, Maisel RH. Angiogenic growth factors: their effects and potential in soft tissue wound healing. Ann. Otol. Rhinol. Laryngol., 1992, 101:349−354.
- Isner J.M., Pieczek A., Schainfeld R. et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaevic limb., Lancet, 1996, 348: 370−374.
- Isner J. M, Baumgartner I., Rauh G., et al. Treatment of thromboangiitis obliterans
- Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results., J.Vase. Surg., 1998, 28: 964−73.
- Joukov V., et al., A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-l (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 1996,15, 290−298.
- Klagsburn M, D’Amore PA. Regulators of angiogenesis. Ann. Rev. Physiol., 1991,53:217−239.
- Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis. Science. 1992- 258:1798−1801.
- Kuwabara K., et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. USA, 1995, 92:46 064 610.
- Kuzuya M., et al., Induction of angiogenesis by smooth muscle cell-derived factor: possible role neovascularization in atherosclerotic plaque., J.Cell.Physiol., 1995, 164, 658−667.
- Laham RJ, Leimbach M, Chronos NS, et al. Intracoronary administration of recombinant fibroblast growth factor (rFGF-2) in patients with severe coronary artery disease: results of phase I. J. Am. Coll. Cardiol., 1999, 33:383A.
- Laitinen M, Hartikainen J, Eranen J, et al. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther., 2000, 110:263 270.
- Laitinen M, Makinen K, Manninen H et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischaemia. Hum. Gene Ther., 1998−9:1481−1486.
- Li J. et al., VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol., 1996, 270: H1803-H1811. (b)
- Li J., et al., VEGF, flk-1 and flt-1 expression in rat myocardial infarction model of angiogenesis., Am.J.Physiol., 1996, 270, H1803-H1811.
- Li J., Hampton T, Morgan J and Simons M. Stretch-induced TGF-P release increases VEGF expression in the heart., Circulation, 1996, 94, 1−285. (a)
- Lindahl P., Hellstrom M., Kalen M., Betsholtz C. Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice. Curr.Opin.Lipidol., 1998, 9: 407−411.
- Losordo D.W., Vale P.R., Symes J.F., et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection ofphVEGF165 as sole therapy for myocardial ischaemia., Circulation, 1998, 98: 2800−2804.
- Makinen K., Laitinen M., Manninen H., et al. Catheter-mediated VEGF gene transfer to human lower limb arteries after РТА., Circulation, 1999, 100: 1−770.
- Mann M.J., Whittemore A.D., Donaldson M.C., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2 °F decoy: the PREVENT single-centre, randomised, controlled trial., Lancet 1999, 354: 1493−1498.
- Maragoudakis ME, Tsopanoglou NE, Sakkoula E, Pipili-Synetos E. On the mechanism of promotion of angiogenesis by thrombin. FASEB J, 1995, 9: A587.
- Maisonpierre PC, et al. Angiopoetin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997, 277:55−60.
- Mori J, Haisa M, Naomoto Y, et al. Suppression of Tumor Growth and Downregulation of Platelet-derived Endothelial Cell Growth Factor / Thymidine Phosphorylase in Tumor Cells by Angiogenesis Inhibitor TNP-470. Jpn. J. Cancer Res, 2000,91:643−650.
- Muhlhauser J, et al., VEGF 165 expressed by a replication-deficient recombinant adenovirus vector induses angiogenesis in vivo., Circulation Res, 1995, 77, 10 771 086.
- Murohara T, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia, J.Clin.Invest, 1998, 101, 11, 2567−2578.
- Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor and insuli-like growth factor-1 promote rat aortic angiogenesis in vitro. Am. J. Pathol, 1994,145:1023−1029.
- Nomura M et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pricytes. J. Biol. Chem., 1995, 270:28 316−28 324.
- Nor J.E. et al., VEGF-mediated angiogenesis is associated with enchanced endothelial cell survival and induction of Bcl-2 expression., Am.J.Pathol., 1999, 154,2:375−383.
- Okamoto T, Akaike T, Suga M, et al. Activation of Human Matrix Metalloproteinases by Various Bacterial Proteinases. J. Biol. Chem., 1997, 272: 6059−6066.
- Olofsson В., et al., Vascular endotelial growth factor B, a novel growth factor for endothelial cells., Proc.Natl. Acad. Sci. U.S.A., 1996, 93, 2576−2581.
- O’Reilly M., et al., Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma., Cell, 1994, 79, 315−328.
- O’Reilly M., et al., Endostatin: An endogenous inhibitor of angiogenesis and tumour growth., Cell, 1997, 88, 277−285.
- Park JE, Chen HH, Winer J, et al. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-l/KDR. J. Bio. Chem., 1994, 269:25 646−25 654.
- Polverini P.J., Cellular adhesion molecules., Am.J.Pathol., 1996, 148, 1023−1029.
- Reddi V., Zaglul A., Pentz E.S., Gomez R.A. Renin-expressing cells are associated with branching of the developing kidney vasculature., J.Am.Soc.Nephrol., 1998, 9: 63−71.
- Risaw W, Drexler H, Mironov V, et al. Platelet-derived growth factor is angiogenic in vivo. Growth factors, 1992, 7:261−266.
- Risau W. Mechanisms of angiogenesis. Nature, 1997, 386:671−674.
- Sasayama S., et al., Recent insights into coronary collateral circulation., Circulation, 1992, 85, 1197−1204.
- Schaper W., Ito W., Molecular mechanisms of collateral vessel growth., Circ.Res., 1996, 79,911−919.
- Schmitt FC, Soares R. TGF-alpha and angiogenesis. American Journal of Surgical Pathology, 1999,23:358−359.
- Selke FW, Jianyi L, Stamler A, et al. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surg., 1996, 120:182−188.
- Selke F.W., et al. Enchanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium., Am.J.Physiol., 1996, 271, H713-H720.
- Selke F.W., et al. Basic FGF enchances endothelium-dependant relaxation of the collateral-perfused coronary microcirculation. Am.J.Physiol., 1994, 267, HI303-H1311.
- Selke FW, Laham RJ, Edelman ER, et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg., 1998, 65:1540−1544.
- Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinicalresults of a new treatment of coronary heart disease., Circulation, 1998, 97: 645 650.
- Shen H., et al., Characterization of VPF/VEGF receptors on mononuclear phagocytes., Blood, 1993, 81, 2767−2773.
- Shweiki D, Itin A, Softer D & Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359:843−845.
- Simons M., Ware J.A., Food for starving hearts., Nature Med., 1996, 2, 519−20.
- Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell. Biol. Int., 1995, 19:431−444.
- Soker S., Takashima S., Maio H.Q., et al., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor., Cell, 1998, 92: 735−745.
- Srekanecz Z., Halloran M.M., Haskell C.J. et al. Vediators of angiogenesis: the role of cellular adhesion molecules., Trends in glycoscience and glycotechnology, 1999, v. ll, 58:73−93.
- Sunderkotter C., et al., Macrophage-derived angiogenesis factors., Pharmacol. Ther., 1991,51, 195−216.
- Suri C, Jones PF, Patan S, et al. Requisite role of angiopoetin-1, a ligand for the TIE2 receptor during embrionic angiogenesis. Cell, 1996, 87:1171−1180.
- Symes JF, Losardo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg., 1999, 68:830−837.
- Taiple J., et al., Vascular endothelial growth factor receptor-3., Curr. Top. Microbiol. Immunol., 1999, 237, 85−96.
- Thurston G, et al. Angiopoetin-1 protects the adult vasculature against plasma leakage. Nature Medicine, 2000, 6:1−4.
- Tschesche H, С Kopp, WH Horl, and U Hempelmann. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment J. Biol. Chem, 1994, 269: 30 274−30 280.
- Tuder R. M, et al. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Fit in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide, J.Clin.Invest, 1995, 95, 1798−1807.
- Westernacher D, Shaper W, A novel heart derived inhibitor of vascular cell proliferation. Purification and biological activity, J.Mol.Cell Cardiol, 1995, 27, 1535−1543.
- Yang FIT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ. Res, 1996, 79:62−69.
- Yang W, Ando J, Korenaga R, et al. Exogegenous nitric oxide inhibits prolipheration of cultured vascular endothelial cells. Biochem. Biophys. Res. Commun, 1994, 203:1160−1167.
- Ziche M, et al. Nitric oxide synthese lies downstream from VEGF-indused but not bFGF-induced angiogenesis, J.Clin.Invest, 1997, 99, 2625−2634.